Letter: golimumab efficacy in patients with Crohn's disease and concomitant severe arthritis
Open Access
- 1 June 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (12), 1449-1451
- https://doi.org/10.1111/apt.15768
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Three‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi‐centre cohort studyAlimentary Pharmacology & Therapeutics, 2019
- Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature reviewBMJ Open, 2019
- Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Scandinavian Journal of Gastroenterology, 2018
- The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s DiseaseJournal of Crohn's and Colitis, 2017
- The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.Inflammatory Intestinal Diseases, 2017
- Efficacy and safety of golimumab in Crohn's disease: a French national retrospective studyAlimentary Pharmacology & Therapeutics, 2017
- Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohortAlimentary Pharmacology & Therapeutics, 2017
- Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisSeminars in Arthritis and Rheumatism, 2017